Celcuity
Clinical-stage biotechnology company that seeks to extend the lives of cancer patients by pursuing an integrated therapeutic and companion diagnostic strategy.
Launch date
Employees
Market cap
€504m
Enterprise valuation
€335m (Public information from Sep 2024)
Share price
$15.19 CELC
Hamel Illinois (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | 5.0m | 3.9m | 61.7m |
| % growth | - | - | - | - | - | (23 %) | 1501 % |
| EBITDA | (9.5m) | (28.3m) | (38.3m) | (58.3m) | (107m) | (129m) | (149m) |
| % EBITDA margin | - | - | - | - | (2117 %) | (3345 %) | (242 %) |
| Profit | (9.5m) | (29.6m) | (40.4m) | (63.8m) | (99.0m) | (143m) | (147m) |
| % profit margin | - | - | - | - | (1964 %) | (3713 %) | (238 %) |
| EV / revenue | - | - | - | - | 91.5x | 153.2x | 9.6x |
| EV / EBITDA | -10.0x | -6.9x | -7.9x | -6.3x | -4.3x | -4.6x | -4.0x |
| R&D budget | 7.7m | 25.8m | 35.3m | 60.6m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | N/A | $5.8m | Convertible |
| N/A | N/A | IPO | |
| N/A | $5.8k | Post IPO Equity | |
| N/A | $3.8k | Convertible | |
| N/A | $24.0m | Post IPO Equity | |
* | $100m | Post IPO Equity | |
* | $100m | Private Placement VC | |
* | N/A | $50.0m | Private Placement VC |
* | N/A | Post IPO Equity | |
* | $61.7m | Post IPO Debt | |
| Total Funding | €152m | ||
Recent News about Celcuity
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.